Literature DB >> 26212263

Targeting the Eph System with Peptides and Peptide Conjugates.

Stefan J Riedl, Elena B Pasquale1.   

Abstract

Eph receptor tyrosine kinases and ephrin ligands constitute an important cell communication system that controls development, tissue homeostasis and many pathological processes. Various Eph receptors/ephrins are present in essentially all cell types and their expression is often dysregulated by injury and disease. Thus, the 14 Eph receptors are attracting increasing attention as a major class of potential drug targets. In particular, agents that bind to the extracellular ephrin-binding pocket of these receptors show promise for medical applications. This pocket comprises a broad and shallow groove surrounded by several flexible loops, which makes peptides particularly suitable to target it with high affinity and selectivity. Accordingly, a number of peptides that bind to Eph receptors with micromolar affinity have been identified using phage display and other approaches. These peptides are generally antagonists that inhibit ephrin binding and Eph receptor/ ephrin signaling, but some are agonists mimicking ephrin-induced Eph receptor activation. Importantly, some of the peptides are exquisitely selective for single Eph receptors. Most identified peptides are linear, but recently the considerable advantages of cyclic scaffolds have been recognized, particularly in light of potential optimization towards drug leads. To date, peptide improvements have yielded derivatives with low nanomolar Eph receptor binding affinity, high resistance to plasma proteases and/or long in vivo half-life, exemplifying the merits of peptides for Eph receptor targeting. Besides their modulation of Eph receptor/ephrin function, peptides can also serve to deliver conjugated imaging and therapeutic agents or various types of nanoparticles to tumors and other diseased tissues presenting target Eph receptors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26212263      PMCID: PMC4861043          DOI: 10.2174/1389450116666150727115934

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  119 in total

1.  EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.

Authors:  Ralf Erber; Uta Eichelsbacher; Violetta Powajbo; Tobias Korn; Valentin Djonov; Jihong Lin; Hans-Peter Hammes; Rainer Grobholz; Axel Ullrich; Peter Vajkoczy
Journal:  EMBO J       Date:  2006-01-19       Impact factor: 11.598

2.  Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.

Authors:  Anita Chaudhari; Magdy Mahfouz; Arsenio M Fialho; Tohru Yamada; Ana Teresa Granja; Yonghua Zhu; Wataru Hashimoto; Beatrix Schlarb-Ridley; Wonhwa Cho; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Biochemistry       Date:  2007-01-24       Impact factor: 3.162

3.  EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures.

Authors:  Ombretta Salvucci; Dragan Maric; Matina Economopoulou; Shuhei Sakakibara; Simone Merlin; Antonia Follenzi; Giovanna Tosato
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

Review 4.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  Eph receptor signaling and ephrins.

Authors:  Erika M Lisabeth; Giulia Falivelli; Elena B Pasquale
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

6.  EphA4 signaling in juveniles establishes topographic specificity of structural plasticity in the hippocampus.

Authors:  Ivan Galimberti; Ewa Bednarek; Flavio Donato; Pico Caroni
Journal:  Neuron       Date:  2010-03-11       Impact factor: 17.173

7.  Dual-modality micro-positron emission tomography/computed tomography and near-infrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models.

Authors:  Miao Huang; Chiyi Xiong; Wei Lu; Rui Zhang; Min Zhou; Qian Huang; Jeffrey Weinberg; Chun Li
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

8.  Regeneration-enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord.

Authors:  Jez Fabes; Patrick Anderson; Caroline Brennan; Stephen Bolsover
Journal:  Eur J Neurosci       Date:  2007-10-26       Impact factor: 3.386

9.  PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.

Authors:  Roberta Noberini; Sayantan Mitra; Ombretta Salvucci; Fatima Valencia; Srinivas Duggineni; Natalie Prigozhina; Ke Wei; Giovanna Tosato; Ziwei Huang; Elena B Pasquale
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

10.  Unique structure and dynamics of the EphA5 ligand binding domain mediate its binding specificity as revealed by X-ray crystallography, NMR and MD simulations.

Authors:  Xuelu Huan; Jiahai Shi; Liangzhong Lim; Sayantan Mitra; Wanlong Zhu; Haina Qin; Elena B Pasquale; Jianxing Song
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

View more
  21 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 2.  EphB4: A promising target for upper aerodigestive malignancies.

Authors:  Ravi Salgia; Prakash Kulkarni; Prakash S Gill
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 10.680

3.  Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.

Authors:  Bernhard C Lechtenberg; Peter D Mace; E Hampton Sessions; Robert Williamson; Romain Stalder; Yann Wallez; Gregory P Roth; Stefan J Riedl; Elena B Pasquale
Journal:  ACS Med Chem Lett       Date:  2017-06-12       Impact factor: 4.345

4.  Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.

Authors:  Maricel Gomez-Soler; Marina Petersen Gehring; Bernhard C Lechtenberg; Elmer Zapata-Mercado; Kalina Hristova; Elena B Pasquale
Journal:  J Biol Chem       Date:  2019-04-23       Impact factor: 5.157

5.  Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability.

Authors:  Erika J Olson; Bernhard C Lechtenberg; Chunxia Zhao; Elena Rubio de la Torre; Ilaria Lamberto; Stefan J Riedl; Philip E Dawson; Elena B Pasquale
Journal:  ACS Med Chem Lett       Date:  2016-06-25       Impact factor: 4.345

Review 6.  Therapeutic potential of targeting the Eph/ephrin signaling complex.

Authors:  Nayanendu Saha; Dorothea Robev; Emilia O Mason; Juha P Himanen; Dimitar B Nikolov
Journal:  Int J Biochem Cell Biol       Date:  2018-10-19       Impact factor: 5.085

7.  A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.

Authors:  Deo R Singh; Elena B Pasquale; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2016-06-06

8.  Improved scFv Anti-LOX-1 Binding Activity by Fusion with LOX-1-Binding Peptides.

Authors:  Wei Hu; Qiuhong Xie; Hongyu Xiang
Journal:  Biomed Res Int       Date:  2017-09-28       Impact factor: 3.411

9.  Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.

Authors:  Marieke A Stammes; Hendrica A J M Prevoo; Meyke C Ter Horst; Stéphanie A Groot; Cornelis J H Van de Velde; Alan B Chan; Lioe-Fee de Geus-Oei; Peter J K Kuppen; Alexander L Vahrmeijer; Elena B Pasquale; Cornelis F M Sier
Journal:  Int J Mol Sci       Date:  2017-02-03       Impact factor: 5.923

10.  Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.

Authors:  Antonio Barquilla; Ilaria Lamberto; Roberta Noberini; Susanne Heynen-Genel; Laurence M Brill; Elena B Pasquale
Journal:  Mol Biol Cell       Date:  2016-07-06       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.